Viridian Therapeutics
VRDN
229 hedge funds and large institutions have $3.36B invested in Viridian Therapeutics in 2025 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 85 increasing their positions, 45 reducing their positions, and 15 closing their positions.
413% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 15
107% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $728K
89% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 45
67% more capital invested
Capital invested by funds: $2.01B → $3.36B (+$1.34B)
36% more funds holding
Funds holding: 169 → 229 (+60)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
1.15% less ownership
Funds ownership: 114.13% → 112.97% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$120M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$58.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$43.3M |
| 4 |
Morgan Stanley
New York
|
+$42.4M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$41.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$81.1M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$78.3M |
| 3 |
CC
Commodore Capital
New York
|
-$69.1M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$47.8M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$32M |
VRDN Hedge Fund Activity: Q4 2025 in Review
229 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2025, worth a combined $3.36B — up 67% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new VRDN positions and 15 closed out — a net gain of 62 holders — while 85 added to existing stakes and 45 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $120M. The largest seller was Kynam Capital Management, cutting an estimated $81.1M.
- 229 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2025, up from 169 in Q3 2025.
- Funds reported $3.36B of Viridian Therapeutics stock for Q4 2025, up 67% quarter-over-quarter.
- 77 funds opened new Viridian Therapeutics positions in Q4 2025 and 15 closed out, a net change of +62 holders.
- The largest Viridian Therapeutics buyer in Q4 2025 was Bellevue Group, an estimated $120M added.
- The largest Viridian Therapeutics seller in Q4 2025 was Kynam Capital Management, an estimated $81.1M sold.
Based on aggregated 13F filings for Q4 2025.